Clinical Observation On The Treatment Of Early Diabetic Nephropathy(qi And Yin Deficiency Syndrome)by Qihuang Capsule

Objective: As compared with placebo,observe the clinical efficacy of Qihuang capsule in the treatment of early diabetic nephropathy(Qi and Yin deficiency syndrome).Methods: 1、The 87 patients with early diabetic nephropathy(Qi and Yin deficiency syndrome) were divided into the test group and the comparison group,and the distribution ratio is 3:1,the test group has 65 cases,the comparison group has 22 cases.During the test,one person exit the test because of adverse events,two person automatically exit the test.Finally, the test group has 63 cases, the comparison group has 21 cases.Through the analysis of before and after treatment between the two groups of UAER、GFR、Cr changes and changes in symptom scores to compare the efficacy of the two groups. 2、Dosing regimen:①The basic treatment:The two groups received standard hypoglycemic treatment(the drugs we choice must has no adverse effect on renal function);All patients used losartan potassium(50mg/times,1time/day), poor control of blood pressure can be combined with other non ACEI/ARB class of antihypertensivedrugs,and when the blood pressure is too,we should reduce or stop to use losartan potassium;All patients must order diabetic diet.② Experimental drugs dosage:The test group was given Qi Huang capsule(5 capsules/time,3 times/day);The comparison group was given Qi Huang capsule simulated agent(5 capsules/time,3 times/day).③Course of treatment:24 weeks of continuous use for a complete course.④The provisions of the combined medications:When subjects were infected,we can use the anti-infection treatment;During the test,in addition to the drugs of the program provided, prohibit the use of other traditional Chinese medicine or Western medicine of diabetic nephropathy,and the other therapies of diabetic nephropathy were also prohibited. 3、The statistic methods: SPSS 19.0 statistical software used for data ananlysis; X2 test used for count data,t test used for measurement data,when P<0.05,it is considered with differences and with statistcal significance.Results: 1.After the treatment,UAER of the test group was significantly different from the comparison group(P<0.05),the test group was better. After 12 weeks of treatment, UAER of the two groups had no significant differences betweent the before and after(P>0.05). After the treatment, UAER of the test group was better than before(P<0.05),and there were no significant differences of the comparison group(P>0.05).After the treatment,Compared with the comparison group,the decline and the rate decline of the test group in UAER were better(P<0.05).The experimental results show that:In the aspect of reducing UAER and reducing micro albumin urine,the effect of the test group was better than the comparison group.2.After the treatment,24 hour urinary protein of the test group was significantly different from the comparison group(P<0.05),the test group was better. After 12 weeks of treatment,24 hour urinary protein of the test group had significant differences betweent the before and after( P < 0.05), and there were no significant differences of the comparison group(P>0.05); After the treatment, 24 hour urinary protein of the two groups were better than before( P < 0.05).After the treatment,Compared with the comparison group,the decline and the rate decline of the test group in 24 hour urinary protein were better(P<0.05). The experimental results show that:In reducing proteinuria,the effect of the test group was better than that of the comparison group. 3.After the treatment,Cr,GFR of the two groups were not significantly different(P>0.05).After the 12 weeks of treatment and the whole treantment,there were no significant differences betweent the two groups in Cr,GFR( P > 0.05).After the treatment,there were no significant differences betweent the two groups of the decline and the rate decline in Cr, GFR(P>0.05). The experimental results show that:The renal function was not significantly improved in the test group. 4.After the treatment, the clinical symptom total score of two groups were better than the before of treatment(P<0.01),and the the test group was better than the comparison group(P <0.01). 5.After the treatment, the obvious efficiency of two groups were not significantly different(P>0.05),but the efficiency and the total efficiency of the two groups were significantly different(P <O.01), it means that the clinical efficacy of the test group was better than the comparison group.6.After the treatment,the Hb A1 c,Fasting blood glucose of the test group and the Hb A1 c of the comparison group were not significantly different(P>0.05),but the Fasting blood glucose of the comparison group was higher than before(P<0.05);After the treatment, the Hb A1 c,Fasting blood glucose of the two groups were not significantly different(P>0.05).Conclusion: As to the patients of early diabetic nephropathy(Qi and Yin deficiency syndrome),Qi Huang capsule has a certain therapeutic in improving clinical symptoms,lowering UAER,reducing proteinuria.